Clinical Trials Browser

Phase 2 × Advanced Pancreatic Cancer × surufatinib × Clear all

NCT06329947 2024-05-08

A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD

Phase 2 Not yet recruiting

Gastrointestinal

Advanced Pancreatic Cancer